Matt Hewitt
Stock Analyst at Craig-Hallum
(2.66)
# 2,172
Out of 5,008 analysts
40
Total ratings
54.05%
Success rate
3.28%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $16.55 | +117.52% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.55 | +83.20% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.62 | +129.01% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $26.52 | +20.66% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $30.52 | +109.70% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $1.51 | +562.25% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $21.29 | +40.91% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $1.65 | +324.24% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $150.10 | +33.24% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $1.68 | +495.24% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $8.57 | +250.06% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.11 | +35,936.04% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $16.55
Upside: +117.52%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.55
Upside: +83.20%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.62
Upside: +129.01%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $26.52
Upside: +20.66%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $30.52
Upside: +109.70%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.51
Upside: +562.25%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $21.29
Upside: +40.91%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $1.65
Upside: +324.24%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $150.10
Upside: +33.24%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.68
Upside: +495.24%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $8.57
Upside: +250.06%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $1.11
Upside: +35,936.04%